3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
7
Carcinoma, Renal Cell
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Interventions
pembrolizumab
29
Nivolumab
12
atezolizumab
7
Cyclophosphamide
7
Paclitaxel
5
Ipilimumab
5
Docetaxel
5
fludarabine
4
avelumab
4
Cisplatin
4
Carboplatin
4
Bevacizumab
4
cemiplimab
3
Leucovorin
3
Gemcitabine
3
Drug Therapy
3
utomilumab
2
ulixertinib
2
tislelizumab
2
poly ICLC
2
milademetan
2
epacadostat
2
durvalumab
2
budigalimab
2
aldesleukin
2
Trastuzumab
2
Standard of Care
2
Specimen Handling
2
Sirolimus
2
Pemetrexed
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
bempegaldesleukin
×
Dermatologic
×
Clear all
NCT02983045
2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2
Completed
557 enrolled
22 charts